1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsFull Proposals Due May 15, 2026 at 5 p.m. US ET. Award announcement anticipated week of September 7, 2026.
Immune Profiling Insights Program is sponsored by The Michael J. Fox Foundation for Parkinson's Research. The Immune Profiling Insights Program is a grant from The Michael J.
Get alerted about grants like this
Save a search for “The Michael J. Fox Foundation for Parkinson's Research” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Immune Profiling Insights Program | Parkinson's Disease Your actions are amplified during Parkinson's Awareness Month. Donate now to accelerate promising research that can't wait. Search for topics, articles, videos, research, etc...
Hit enter to search or ESC to close Immune Profiling Insights Program Immune Profiling Insights Program This program supports research that deepens understanding of how specific components of the immune system contribute to Parkinson’s disease risk, onset and progression. The goal is to pinpoint immune cell populations, signaling pathways and functional states that change throughout the Parkinson's continuum.
The program also seeks to understand how these immune features connect to clinical outcomes and disease progression, driving future therapeutic targeting and patient selection for future clinical studies.
MJFF will prioritize proposals that: Use validated immunophenotyping and functional assays on banked biosamples (e.g., PBMCs, CSF-derived cells, GI immune cells) to generate mechanistic, hypothesis-driven data clarifying immune involvement in PD risk, onset or progression.
Leverage and strengthen collaborations that enable access to diverse, well-characterized PD cohorts (genetic, idiopathic, prodromal/at-risk), utilizing existing clinical, genetic and longitudinal data where possible to study immune differences across subtypes and stages.
Integrate immune functional readouts with existing data from established and emerging PD biomarkers or other immune data (such as TSPO imaging, cytokine measurements), aiming to correlate immune signatures with molecular, pathological, or clinical markers to identify immune features linked to disease heterogeneity, progression or patient stratification.
MJFF will not consider proposals focused on: Developing new immunophenotyping platforms. Discovery-driven efforts (e.g. ‘omics) without an underlying hypothesis. Prospective sample collection.
Generation of new imaging or digital endpoint data. Solely assessing post-mortem autopsy samples or iPSCs. Cytokine profiling in biofluids (unless correlating existing cytokine data with other immune readouts).
Immune profiling in non-PD cohorts. Analysis of existing immune datasets (though future opportunities may be available; contact grants@michaeljfox. org ) Please note that MJFF has an Open Science Policy which governs research outputs (such as preprints, journal articles, data, code, and software) resulting from MJFF-funded work.
The Open Science Policy applies to this funding program and includes specific rules, timing, and format for the return of those research outputs and requires them to be shared openly, to be free to access, and with persistent identifiers. Please contact openscience@michaeljfox. org for questions about the Open Science Policy.
Here. Until Parkinson's isn't. Help us speed a cure for the 6 million people worldwide living with Parkinson's.
Join our email list to get the latest news and resources directly to your inbox. Connection to Parkinson's Immediate family member has PD Immediate family member had PD Extended family member or friend has PD Extended family member or friend had PD I am a researcher, clinician or work with the PD community What Year Were You Diagnosed with PD?
Based on current listing details, eligibility includes: Research must use validated immunophenotyping on banked biosamples (PBMCs, CSF-derived cells, GI immune cells) leveraging diverse, well-characterized PD cohorts with existing clinical/genetic data. No new platform development or prospective sample collection. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates $3,000,000 total program commitment Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is May 15, 2026. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.